These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 31000722

  • 1. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
    Tang C, Sun R, Wen G, Zhong C, Yang J, Zhu J, Cong Z, Luo X, Ma C.
    Cell Death Dis; 2019 Apr 18; 10(5):335. PubMed ID: 31000722
    [Abstract] [Full Text] [Related]

  • 2. Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.
    Tang C, Zhu J, Yuan F, Yang J, Cai X, Ma C.
    Mol Neurobiol; 2021 Dec 18; 58(12):6170-6185. PubMed ID: 34463926
    [Abstract] [Full Text] [Related]

  • 3. ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
    Zhu J, Tang C, Cong Z, Yuan F, Cai X, Yang J, Ma C.
    Endocr Relat Cancer; 2021 Dec 13; 29(2):33-46. PubMed ID: 34821219
    [Abstract] [Full Text] [Related]

  • 4. Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline.
    Lin SJ, Leng ZG, Guo YH, Cai L, Cai Y, Li N, Shang HB, Le WD, Zhao WG, Wu ZB.
    Oncotarget; 2015 Nov 17; 6(36):39329-41. PubMed ID: 26513171
    [Abstract] [Full Text] [Related]

  • 5. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
    Jian M, Du Q, Zhu D, Mao Z, Wang X, Feng Y, Xiao Z, Wang H, Zhu Y.
    J Endocrinol Invest; 2019 Jun 17; 42(6):639-652. PubMed ID: 30370446
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.
    Zhang SL, Tang HB, Hu JT, Zang ZL, Ding X, Li S, Yang H.
    Biomed Pharmacother; 2019 Mar 17; 111():638-648. PubMed ID: 30611988
    [Abstract] [Full Text] [Related]

  • 10. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
    Kawabata Y, Ueno Y, Horikawa F, Miyake H, Miki N, Ono M.
    Surg Neurol; 2008 Jan 17; 69(1):85-8; discussion 88. PubMed ID: 17967478
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.
    Huang HY, Lin SJ, Zhao WG, Wu ZB.
    Metab Brain Dis; 2018 Jun 17; 33(3):969-976. PubMed ID: 29546691
    [Abstract] [Full Text] [Related]

  • 13. Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
    Xiao Z, Liang J, Deng Q, Song C, Yang X, Liu Z, Shao Z, Zhang K, Wang X, Li Z.
    Int J Mol Med; 2021 Jan 17; 47(1):113-124. PubMed ID: 33155660
    [Abstract] [Full Text] [Related]

  • 14. Prolactinomas, cabergoline, and pregnancy.
    Glezer A, Bronstein MD.
    Endocrine; 2014 Sep 17; 47(1):64-9. PubMed ID: 24985062
    [Abstract] [Full Text] [Related]

  • 15. Management of Dopamine Agonist-Resistant Prolactinoma.
    Maiter D.
    Neuroendocrinology; 2019 Sep 17; 109(1):42-50. PubMed ID: 30481756
    [Abstract] [Full Text] [Related]

  • 16. DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma.
    Yao H, Tang H, Zhang Y, Zhang QF, Liu XY, Liu YT, Gu WT, Zheng YZ, Shang HB, Wang Y, Huang JY, Wei YX, Zhang X, Zhang J, Wu ZB.
    Cancer Lett; 2019 Sep 10; 459():135-144. PubMed ID: 31176743
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2000 Jul 10; 53(1):53-60. PubMed ID: 10931080
    [Abstract] [Full Text] [Related]

  • 19. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A.
    J Clin Endocrinol Metab; 2001 Nov 10; 86(11):5256-61. PubMed ID: 11701688
    [Abstract] [Full Text] [Related]

  • 20. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
    Arduc A, Gokay F, Isik S, Ozuguz U, Akbaba G, Tutuncu Y, Berker D, Kucukler FK, Aydin Y, Guler S.
    J Endocrinol Invest; 2015 Apr 10; 38(4):447-53. PubMed ID: 25421155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.